Botulinum Toxin A Ameliorates Neuroinflammation in the MPTP and 6-OHDA-Induced Parkinson’s Disease Models

Recently, increasing evidence suggests that neuroinflammation may be a critical factor in the development of Parkinson’s disease (PD) in addition to the ratio of acetylcholine/dopamine because dopaminergic neurons are particularly vulnerable to inflammatory attack. In this study, we investigated whe...

Full description

Saved in:
Bibliographic Details
Published in:Biomolecules & therapeutics 2022-01, Vol.30 (1), p.90-97
Main Authors: Ham, Hyeon Joo, Yeo, In Jun, Jeon, Seong Hee, Lim, Jun Hyung, Yoo, Sung Sik, Son, Dong Ju, Jang, Sung-Su, Lee, Haksup, Shin, Seung-Jin, Han, Sang Bae, Yun, Jae Suk, Hong, Jin Tae
Format: Article
Language:Korean
Subjects:
Anti-neuroinflammation
Botulinum toxin A
Parkinson’s disease
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recently, increasing evidence suggests that neuroinflammation may be a critical factor in the development of Parkinson’s disease (PD) in addition to the ratio of acetylcholine/dopamine because dopaminergic neurons are particularly vulnerable to inflammatory attack. In this study, we investigated whether botulinum neurotoxin A (BoNT-A) was effective for the treatment of PD through its anti-neuroinflammatory effects and the modulation of acetylcholine and dopamine release. We found that BoNT-A ameliorated MPTP and 6-OHDA-induced PD progression, reduced acetylcholine release, levels of IL-1β, IL-6 and TNF-α as well as GFAP expression, but enhanced dopamine release and tyrosine hydroxylase expression. These results indicated that BoNT-A had beneficial effects on MPTP or 6-OHDA-induced PD-like behavior impairments via its anti-neuroinflammation properties, recovering dopamine, and reducing acetylcholine release.
ISSN:1976-9148
2005-4483